Clinical Trial Update: Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating QLS32015 in combination therapy for relapsed or refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• QLS32015 (QLS32015)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 2 | Status: RECRUITING